Danaher (NYSE:DHR)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They currently have a $114.00 target price on the conglomerate’s stock, up from their prior target price of $108.00. Stifel Nicolaus’ price target indicates a potential upside of 12.49% from the company’s previous close.
A number of other analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $109.00 target price for the company in a research note on Wednesday, April 11th. Morgan Stanley lifted their target price on shares of Danaher from $110.00 to $112.00 and gave the company an “overweight” rating in a research note on Tuesday, April 10th. ValuEngine upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Credit Suisse Group lifted their target price on shares of Danaher from $106.00 to $108.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. Finally, Deutsche Bank reduced their target price on shares of Danaher from $114.00 to $107.00 and set a “buy” rating for the company in a research note on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $104.53.
DHR stock opened at $101.34 on Thursday. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39. The company has a market cap of $71,431.12, a P/E ratio of 25.15, a P/E/G ratio of 1.94 and a beta of 1.03. Danaher has a 52 week low of $78.97 and a 52 week high of $104.82.
In related news, EVP William K. Daniel sold 131,066 shares of the business’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the transaction, the executive vice president now owns 270,523 shares of the company’s stock, valued at $27,606,872.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rainer Blair sold 3,981 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $100.05, for a total transaction of $398,299.05. Following the transaction, the insider now directly owns 49,751 shares in the company, valued at approximately $4,977,587.55. The disclosure for this sale can be found here. Insiders sold 313,260 shares of company stock valued at $31,657,786 over the last 90 days. 11.90% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Calton & Associates Inc. bought a new position in Danaher during the fourth quarter worth $114,000. First Personal Financial Services increased its position in Danaher by 128.9% during the fourth quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock worth $114,000 after acquiring an additional 691 shares during the period. CNB Bank bought a new position in Danaher during the fourth quarter worth $116,000. Truewealth LLC bought a new position in Danaher during the fourth quarter worth $121,000. Finally, Resources Investment Advisors Inc. increased its position in Danaher by 661.2% during the fourth quarter. Resources Investment Advisors Inc. now owns 1,530 shares of the conglomerate’s stock worth $142,000 after acquiring an additional 1,329 shares during the period. 77.65% of the stock is currently owned by institutional investors and hedge funds.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.